NF-κB Upregulates Type 5 Phosphodiesterase in N9 Microglial Cells: Inhibition by Sildenafil and Yonkenafil
- 25 June 2015
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 53 (4) , 2647-2658
Abstract
Our previous studies showed that the phosphodiesterase-5 (PDE5) inhibitor sildenafil inhibited the microglial activation induced by lipopolysaccharide (LPS). However, whether yonkenafil, a novel PDE5 inhibitor, also inhibits microglial activation and the underlying mechanism of inhibition remain elusive. Here we found that yonkenafil significantly suppressed the production of NO, interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) and the protein expression of inducible NO synthase (iNOS) induced by LPS in microglial cells in a concentration-dependent manner. Knockdown of PDE5 inhibits NO and iNOS protein expression in LPS-stimulated N9 microglia. Moreover, we observed that the nuclear factor-κB (NF-κB) transcriptionally upregulated PDE5 expression, which was inhibited by sildenafil and yonkenafil in LPS-stimulated N9 microglia. Therefore, sildenafil and yonkenafil may exert their inhibitory effects on microglial activation by reducing the expression of PDE5. Furthermore, sildenafil and yonkenafil increased the cyclic guanosine monophosphate (cGMP) level in N9 microglia, and 8-Br-cGMP, an analogue of cGMP, downregulates extracellular signal-regulated kinases 1 and 2 (ERK1/2)/the NF-κB pathway, suggesting that sildenafil and yonkenafil inhibit microglial activation by decreasing PDE5 expression and increasing the cGMP level. Importantly, sildenafil and yonkenafil significantly alleviated the death of SH-SY5Y neuroblastoma cells and primary cortical neurons induced by the conditioned medium from activated microglia. Together, these findings position PDE5 as a potential therapy target for the treatment of neuroinflammation accompanied by microglial activation.Keywords
This publication has 33 references indexed in Scilit:
- Regulation of NF-κB by TNF family cytokinesSeminars in Immunology, 2014
- Sildenafil Mediates Blood-Flow Redistribution and Neuroprotection After Neonatal Hypoxia-IschemiaStroke, 2014
- Regulation of Hippocampal cGMP Levels as a Candidate to Treat Cognitive Deficits in Huntington’s DiseasePLOS ONE, 2013
- Metallothioneins I/II are involved in the neuroprotective effect of sildenafil in focal brain injuryNeurochemistry International, 2013
- Tissue plasminogen activator induces microglial inflammation via a noncatalytic molecular mechanism involving activation of mitogen‐activated protein kinases and Akt signaling pathways and AnnexinA2 and Galectin‐1 receptorsGlia, 2011
- Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5ACancer Cell, 2011
- Pharmacokinetic–Pharmacodynamic Analysis of the Static Allodynia Response to Pregabalin and Sildenafil in a Rat Model of Neuropathic PainThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Microglia rules: insights into micoglial–neuronal signalingCell Death & Differentiation, 2004
- β‐Amyloid Vasoactivity and Proinflammation in Microglia Can Be Blocked by cGMP‐Elevating AgentsAnnals of the New York Academy of Sciences, 2000
- Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMPThe FASEB Journal, 1999